Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Maintenance in High-Risk DLBCL/FL
NCT03600363Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Overall Survival at 100 months. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03600363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600363.